


SYNTHESIS OF A NEW 10-MEMBERED RING FUNCTIONALISED CYCLODIYNOL RELATED TO NEOCARZINOSTATIN CHROMOPHORE

Jean Suffert

Laboratoire de Stéréochimie Organométallique, EHICS
1, rue Blaise Pascal, 67000 Strasbourg France

Summary: The diyne system **5** is synthesized from 2-bromobenzaldehyde in eight steps through an intramolecular allylsilane-terminated cyclisation.

The antitumor agent neocarzinostatin **1**¹ was discovered in 1965, but its structure was only unambiguously assigned² in 1985. It consists of a protein subunit non-covalently complexed to a very labile non-protein chromophore **1** (so called NCS chrom). The unusual structure of this and related compounds calicheamicin³, esperamicin⁴, dynemicin⁵ as well as their very high activity as antitumor agents has generated interest in the synthesis of cyclic molecules containing an enediyne system⁶.




It was recently demonstrated that the bicyclic core plays an important role in the mechanism of action of NCS chrom **1**⁷. This highly strained unsaturated bicyclo[7,3,0]-dodecadienediyne nucleus is very unstable and is rapidly deactivated by UV light or by nucleophiles⁸.


In the presence of a thiol under aerobic conditions, NCS chrom **1** binds to DNA by intercalation of the naphthoate ester, thus positioning the strained bicyclic system in the minor groove of DNA and selectively cleaving the desoxythymidine and deoxyadenosine residues⁹. Evidence to support that the active intermediate is the biradical **2**, which

abstracts hydrogen from DNA has been obtained¹⁰. Such a biradical has also been proposed for the action of calicheamicin, esperamicin¹¹ and dynemicin¹².

The design and synthesis of new molecules containing properly positioned triple bonds which mimic the biological activity of NCS chrom 1, but which are more stable, are of interest as chemotherapeutic agents. We recently reported the first synthesis of the parent carbocyclic subunit **3a** of NCS chrom 1¹³, and showed the instability of such a 9-membered ring (half-time life \approx 48h at 20°C). Related compound **3b**¹⁴ and the 10-membered ring analogue **4**¹⁵ have been synthesized.



We present here the synthesis of the enediyne system **5**, which may undergo rapid cyclisation upon removal of the tBDMS group to provide a diradical species. Thus, reaction of (trimethylsilyl)acetylene with 2-bromobenzaldehyde using a modified Lau¹⁶ procedure, (Pd(PPh₃)₃Cl₂/CuI; THF/Et₃N 5/1; 25°C), gave the 2-[(trimethylsilyl)ethynyl]benzaldehyde **6** in 80% yield. Addition to **6** of the Grignard reagent prepared from THP-protected propargylic alcohol by treatment with EtMgBr, followed by deprotection of the TMS group by K₂CO₃/MeOH¹⁶ provided the secondary alcohol **8** (90% yield for the 2 steps) as a mixture of inseparable diastereomers¹⁷. This secondary alcohol was protected with tBDMSCl in the presence of imidazole in DMF¹⁸ at 20°C to afford **9** in 85% yield. The coupling of the terminal alkyne **9** with 2-bromoallyltrimethylsilane¹⁹ in the presence of a catalytic amount of Pd(PPh₃)₃Cl₂/CuI in a mixture of THF/iPr₂NH 5/1 at 20°C for 4h led to the propargylic allylsilane **10** in 94% yield. The selective deprotection of the THP group of **10** in the presence of PPTS in EtOH or MeOH gave **11** respectively in only 53% and 62% yields. However reaction of **10** with PPTS in iPrOH furnished the desired propargylic alcohol **11** in 81% yield. The next goal in this synthesis was the oxidation of alcohol **11** into the aldehyde **12**. Several classical oxidation procedures like PCC²⁰, PCC/4Å sieves²¹, Swern oxidation²² or MnO₂²³ only produced a low yield of **12** or degradation products. Eventually this oxidation was successfully achieved following the Saigo²⁴ procedure: reaction of **11** with tBuOMgBr in THF at -25°C followed by addition of 1,1-(azodicarbonyl)dipiperidine and slowly warming the solution to 20°C provided **12**, isolated in 90% yield as a clear yellow oil.



Intramolecular cyclisations using allylsilanes has been reported by several group²⁵. The key reaction to induce the cyclisation of compound 11 was based on the property of allylsilanes to attack aldehydes or ketones in the presence of a Lewis acid or a fluoride anion^{26,27}. Thus, when 12 was treated at -78°C in CH_2Cl_2 with 3 equivalents of $\text{BF}_3 \cdot \text{Et}_2\text{O}$, 5 was isolated in 47% yield as a mixture of two separable diastereomers 5a and 5b in a ratio 1/1. The structures of both diastereomers were confirmed by $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, IR, and MS analysis²⁸. Both diastereomers are crystalline compounds, stable at room temperature and can be stored at -40°C without degradation. Several other Lewis acids such TiCl_4 , SnCl_4 , Et_2AlCl , Me_2AlCl or $n\text{Bu}_4\text{NF}$ gave lower yields or degradation products.

Experiments to improve this cyclisation and synthesis of other analogs of 5, as well as preliminary biological tests on the ability of 5 to cleave DNA are in progress and will be reported in due course.

Acknowledgements: We thank the CNRS for financial support and Dr. A.Solladié-Cavallo for research facilities.

References and Notes

1. N.Ishida, K.Miyasaki, K.M.Kumagai, M. Rikimura, *J.Antibiot.*, **1965**, *18*, 68
2. K.Edo, M.Mizugaki, Y.Koide, H.Seto, K.Furihata, N.Otake, N.Ishida, *Tetrahedron Lett.*, **1985**, *26*, 331
3. M.D.Lee, T.S.Dune, M.M.Siegel, C.C.Chang, G.O.Morton, D.B.Borders, *J.Am.Chem.Soc.*, **1987**, *109*, 3464; M.D.Lee, T.S.Dune, C.C.Chang, G.A.Ellestad, M.M.Siegel, G.O.Morton, D.B.Borders, *J.Am.Chem.Soc.*, **1987**, *109*, 3466
4. M.Konishi, H.Ohkuma, K.Saitoh, H.Kawagushi, J.Golik, G.Dubay, G.Groenwold, B.Krishnan, T.W.Doyle, *J.Antibiot.*, **1985**, *38*, 1605; J. Golik, J.Clardy, G.Dubay, G.Groenwold, H.Kawagushi, M.Konishi, B.Krishnan, H.Ohkuma, K.Saitoh, T.W.Doyle, *J.Am.Chem.Soc.*, **1987**, *109*, 3461; J.Golik, G.Dubay, G.Groenwold, H.Kawagushi, M.Konishi, B.Krishnan, H.Ohkuma, K.Saitoh, T.W.Doyle, *J.Am.Chem.Soc.*, **1987**, *109*, 3462
5. M.Konishi, H.Ohkuma, K.Matsumoto, T.Tsuno, H.Kamei, T.Miyaki, T.Oki, H.Kawagushi, G.D.Van Duyne, J.Clardy, *J.Antibiot.*, **1989**, *42*, 1449

6. R.Nagata, H.Yamanaka, E.Okazaki, I.Saito, *Tetrahedron Lett.*, **1989**, *30*, 4995; S.J.Danishefsky, D.S.Yamashita, N.B.Mantlo, *Tetrahedron Lett.*, **1988**, *29*, 4681; K.C.Nicolaou, G.Zuccarello, H.Kataoka, *J.Am.Chem.Soc.*, **1988**, *110*, 4866; K.C.Nicolaou, Y.Ogawa, G.Zuccarello, H.Kataoka, *J.Am.Chem.Soc.*, **1988**, *110*, 7247; A.G.Myers, P.S.Dragowich, *J.Am.Chem.Soc.*, **1989**, *111*, 9130; K.C.Nicolaou, G.Skokotos, P.Maligres, G.Zuccarello, E.J.Schweiger, K.Toshima, S.Wendeborn, *Angew.Chem.Int.Ed.Engl.*, **1989**, *28*, 1272
7. Y.Koide, A.Ito, K.Edo, N.Ishida, *Chem.Pharm.Bull.*, **1986**, *34*, 4425
8. D.Dasgupta, I.H.Goldberg, *Biochemistry*, **1985**, *24*, 6913; M.A.Napier, I.H.Goldberg, *Molecular Pharmacologie*, **1982**, *23*, 500
9. T.Hatayama, I.H.Goldberg, M.Takeshita, A.P.Grollmann, *Proc.Natl.Acad.Sci.USA*, **1978**, *75*, 3603; M.Takeshita, L.S.Kappen, A.P.Grollmann, M.Eisenberg, I.H.Goldberg, *Biochemistry*, **1981**, *20*, 7599
10. A.G.Myers, *Tetrahedron Lett.* **1987**, *28*, 4493; A.G.Myers, P.J.Proteau, T.M.Handel, *J.Am.Chem.Soc.*, **1988**, *110*, 7212; A.G.Myers, P.J.Proteau, *J.Am.Chem.Soc.*, **1989**, *111*, 1146
11. J.P.Snyder, *J.Am.Chem.Soc.*, **1989**, *111*, 7630
12. J.P.Snyder, G.E.Tipsword, *J.Am.Chem.Soc.* **1990**, *112*, 4040
13. P.A.Wender, M.Harmata, D.M.Jeffrey, C.Mukai, J.Suffert, *Tetrahedron Lett.* **1988**, *29*, 909
14. P.A.Wender, J.A.McKinney, C.Mukai, *J.Am.Chem.Soc.*, **1990**, *112*, 5369
15. M.Hirama, K.Fujiwara, K.Shigematu, Y.Fukazawa, *J.Am.Chem.Soc.*, **1989**, *111*, 4120; K.Fujiwara, A.Kurisasi, M.Hirama, *Tetrahedron Lett.*, **1990**, *31*, 4329
16. W.B.Austin, N.Bilow, W.J.Kelleghan, K.S.Y.Lau, *J.Org.Chem.*, **1981**, *46*, 2280
17. All new compounds show spectroscopic data as well as elemental analysis in agreement with their proposed structures.
18. E.J.Corey, A.Venkateswarlu, *J.Am.Chem.Soc.*, **1972**, *94*, 6190
19. N.Furuya, T.Sukawa, *J.Organomet.Chem.*, **1975**, *96*, C1-C3
20. E.J.Corey, J.W.Suggs, *Tetrahedron Lett.*, **1975**, 2647
21. K.C.Nicolaou, D.D.Papahatjis, D.A.Claremon, R.L.Magolda, R.E.Dolle, *J.Org.Chem.*, **1985**, *50*, 1440
22. A.J.Mancuso, D.Swern, *Synthesis*, **1981**, 165
23. A.J.Fatiadi, *Synthesis*, **1976**, 133
24. K.Narasaka, A.Morikawa, K.Saigo, T.Mukaiyama, *Bull.Chem.Soc.Jpn.*, **1977**, *50*, 2773
25. For an excellent review see, D.Schinzer, *Synthesis*, **1988**, 263; T.A.Blumenkopf, L.E.Overmann, *Chem.Rev.*, **1986**, *86*, 857
26. T.K.Sarkar, N.H.Anderson, *Tetrahedron Lett.*, **1978**, 3513
27. S.E.Denmark, E.J.Weber, *Helv.Chim.Acta*, **1983**, *66*, 1655; *J.Am.Chem.Soc.*, **1984**, *106*, 7970
28. Selected physical parameters of new compounds **12**, **5a** and **5b** :
12 IR(film) ν 2940, 2850, 2240, 2180, 1670, and 1250 cm^{-1} ; $^1\text{H-NMR}$ 200MHz(CDCl_3) δ 0.11(6H, s, SiMe_2), 0.13(9H, s, SiMe_3), 0.93(9H, s, tBu), 1.79(2H, d, $^4J=0.8\text{Hz}$, CH_2SiMe_3), 5.15(1H, d, $^2J=1.8\text{Hz}$, vinylic H), 5.33(1H, d, $^2J=1.8\text{Hz}$, vinylic H), 6.03(1H, s, CHOtBDMS), 7.26-7.70(4H, m, aro.), 9.22(1H, s, CHO); $^{13}\text{C-NMR}$ 50MHz(CDCl_3) δ -4.99, -4.78, -1.62, 0.52, 18.23, 25.67, 28.00, 62.85, 83.61, 85.00, 96.28, 97.60, 119.71, 120.91, 126.38, 128.20, 128.56, 128.79; 131.97, 141.00; 176.51; **5a** $\text{C}_{21}\text{H}_{26}\text{O}_2\text{Si}$ MS-Cl(NH_3) [$\text{M}+\text{NH}_4$] $^+$ 356; IR(CHCl_3) ν 3590, 2950, 2920, 2850, 2235, 1620, 1460, 1375, 1250, cm^{-1} ; $^1\text{H-NMR}$ 200MHz(CDCl_3) δ 0.19(3H, s, SiCH_3), 0.20(3H, s, SiCH_3), 0.95(9H, s, tBu), 2.03(1H, broad s, OH), 2.72(2H, AB part of an ABX system, $J_{\text{AB}}=24\text{Hz}$, $J_{\text{AX}}=7.3\text{Hz}$, $J_{\text{BX}}=3.5\text{Hz}$, $\Delta\nu=31\text{Hz}$, allylic CH_2), 4.55(1H, m, X part of ABX system, CHOH), 5.38(1H, d, $^2J=1.6\text{Hz}$, vinylic H), 5.50(1H, d, $^2J=1.6\text{Hz}$, vinylic H), 5.65(1H, s, CHOtBDMS), 7.21-7.53(4H, m, aro.); $^{13}\text{C-NMR}$ 50MHz(CDCl_3) δ -4.77, -4.22, 18.26, 25.80, 44.54, 61.55, 64.09, 87.22, 88.43, 92.79, 96.16, 120.48, 123.14, 126.52, 127.47, 128.05, 128.65, 132.09, 140.76; **5b** $\text{C}_{21}\text{H}_{26}\text{O}_2\text{Si}$ MS-Cl(NH_3) [$\text{M}+\text{NH}_4$] $^+$ 356; IR(CHCl_3) ν 3590, 2950, 2920, 2850, 2235, 1620, 1460, 1375, 1250, cm^{-1} ; $^1\text{H-NMR}$ 200MHz(CDCl_3) δ 0.20(6H, s, $\text{Si}(\text{CH}_3)_2$), 0.96(9H, s, tBu), 1.90(1H, broad s, OH), 2.73(2H, AB part of ABX system, $J_{\text{AB}}=25\text{Hz}$, $J_{\text{AX}}=7\text{Hz}$, $J_{\text{BX}}=3.3\text{Hz}$, $\Delta\nu=33\text{Hz}$, allylic CH_2), 4.58(1H, X part of ABX system, ddd, $J_{\text{AX}}=7\text{Hz}$, $J_{\text{BX}}=3.3\text{Hz}$, $^5J=1.3\text{Hz}$, CHOH), 5.39(1H, d, $^2J=1.5\text{Hz}$, vinylic H), 5.51(1H, d, $^2J=1.5\text{Hz}$, vinylic H), 5.64(1H, s, CHOtBDMS), 7.22-7.54(4H, m, aro); $^{13}\text{C-NMR}$ 50MHz(CDCl_3) δ -4.77, -4.21, 18.28, 25.83, 44.08, 61.42, 63.95, 87.27, 88.63, 92.90, 96.17, 120.46, 123.56, 126.45, 127.46, 127.75, 128.70, 132.22, 140.79.